


MODEL U-SES

Feature

- MODEL U-SES trial demonstrated that 3-month DAPT was non inferior to adjusted cohort of longer DAPT after BP-SES implantation in net adverse clinical events.
- P2Y12 inhibitor monotherapy was almost equivalent to Aspirin monotherapy after 3 months in terms of both bleeding and thrombotic events.

Short VS Long


DAPT discontinuation



Landmark analysis: Efficacy and Safety


Landmark Analysis at 90 days: Cardiovascular death, MI, Stroke and ST

With Propensity Score Adjustment



Landmark Analysis at 90 days: Bleeding (BARC 3 or 5)


With Propensity Score Adjustment



Comparison of Single Antiplatelet Therapy: Aspirin and P2Y12 receptor inhibitors


Landmark Analysis at 90 days: Cardiovascular death, MI, Stroke and ST

With IPTW Analysis




Landmark Analysis at 90 days: Bleeding (BARC 3 or 5)

With IPTW Analysis



Study design



Patient background comparison with historical control

	MODEL U-SES (n=1,695)	CENTURY II (n=549)	p-Value
Age, years	69.7±10.6	65.3±10.5	< 0.001
Age >75 years	36.2%	19.7%	< 0.001
Male gender	76.8%	78.5%	0.41
Body mass index, kg/m ²	24.3±3.5	27.0±4.1	< 0.001
Diabetes	39.3%	32.2%	0.003
Hypertension	79.9%	73.7%	0.002
Current smoker	21.7%	22.4%	0.72
Severe CKD	13.0%	4.0%	< 0.001
Hemodialysis	5.3%	2.0%	0.001
Prior stroke	10.4%	3.8%	< 0.001
Heart failure	27.2%	29.3%	0.35
Peripheral vascular disease	6.7%	9.7%	0.03

Reference

Ken Kozuma, 3-month discontinuation of dual antiplatelet therapy after bioresorbable polymer sirolimus-eluting stent implantation: MODEL U-SES study presented at TCT 2018



Presentation on TCT online >

Contact

Link to contact page



- Detailed specification
- Clinical evidence
- Support

